Adcirca Benefits Patients in Two Pulmonary Hypertension Categories, Trials Show
Patients with pulmonary arterial hypertension (PAH) caused by connective tissue disease benefit from treatment with Adcirca (tadalafil), but their outcomes aren’t as good as patients with idiopathic PAH, an analysis of data from two clinical trials indicates. Safety was a particular problem with connective tissue disease patients, the evaluation…